Blocking LIF and PD-L1 enhances the antitumor efficacy of SBRT in murine PDAC modelsjeanfrancoismaisonMay 101 min readRated NaN out of 5 stars.https://pubmed.ncbi.nlm.nih.gov/40341024/
ANGPTL3: A Breakthrough Target in Treatment for Dyslipidemia and Atherosclerosishttps://pubmed.ncbi.nlm.nih.gov/40467521/
Targeting CD117 on hematopoietic stem and progenitor cells impairs CAR T cell activityhttps://pubmed.ncbi.nlm.nih.gov/40450523/
Comments